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 Introduction 
 Cutaneous squamous cell carcinoma (cSCC) is a com-
mon skin cancer with an incidence rate of 12–29/100,000/
year in Europe and 700/100,000/year in Australia  [1–7] . 
Populations with fair skin that experience high cumula-
tive UV exposure are at highest risk for cSCC develop-
ment, sun-exposed areas being majorly affected  [8–10] .
 The treatment of choice for invasive cSCC is surgery, 
particularly Mohs micrographic surgery  [11–16] produc-
ing the lowest recurrence rates. In elderly patients with 
problematic co-morbidities and critical tumor localiza-
tions, radiotherapy (RTx) can be an alternative option 
 [11–26] , but reports of superficial RTx and data on long-
term outcome are limited  [17, 19–20, 22] .
 In the following, relapse rates of cSCCs after superfi-
cial RTx are reported from a retrospective study. Data are 
correlated with the tumors’ histological differentiation 
and anatomical distribution.
 Patients and Methods 
 The present retrospective study included all patients with 
cSCCs who were treated with superficial RTx at the Department 
of Dermatology, University Hospital of Zurich, Switzerland dur-
ing 1960–2004. The patients were treated with Dermax 4000 fol-
lowing standard guidelines if surgical excision was not favored by 
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 Abstract 
 Background: Surgical excision is the gold standard for cuta-
neous squamous cell carcinoma (cSCC), however its applica-
tion is limited in specific cases. Superficial radiotherapy (RTx) 
is an alternative treatment option, but long-term follow-up 
data are limited.  Objective: To determine the outcome of 
superficial RTx of cSCC in correlation to histological differen-
tiation grade and tumor localization.  Methods: The outcome 
of 180 large cSCCs after superficial RTx between 1960 and 
2004 was retrospectively reviewed.  Results: Mean tumor 
size was 3.5 cm 2 (SD 7.5) and mean follow-up period was 4.9 
years (SD 4.7). Relapse-free survival was 95.8 and 80.4% after 
1 and 10 years. Two-year relapse-free survival was 94.8% for 
good, 88.9% for moderate and 85.7% for poor differentiated 
tumors. Five-year relapse-free survival was highest in cSCCs 
located around the eyes (100%) and cheeks (90.9%).  Conclu-
sion: Superficial RTx is an effective alternative for cSCC if sur-
gery is difficult due to localization or concomitant disease. 
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the patients (mostly due to the patient’s co-morbidities combined 
with tumor size and localization). The decision to treat with RTx 
instead of surgery was individually taken by the physician togeth-
er with the patient. Overall, patients were offered treatment with 
superficial RTx if they were of high age and presented a lesion of 
large size or localized at difficult sites. Patients who were lost to 
follow-up were sent a new appointment for consultation. Patients 
treated after 2004 were not included in the study in order to keep 
a standard as the equipment changed afterwards.
 The diagnoses were histologically confirmed by H&E staining 
prior to treatment. Lesion size was measured by multiplying the 
two largest diameters that were perpendicular to each other. Su-
perficial RTx was performed using Dermax 4000, a beryllium-
windowed soft X-ray machine (R. Liechti AG, Kriegstetten, Swit-
zerland) using 10, 20, 30, 40 or 50 kV. A field margin of 1 cm to 
the clinical tumor edges was applied. The administered electric 
potential ranged from 30 to 60 kV. Depending on the thickness of 
the interposed aluminum filter (0.5–2.0 cm), the electric current 
(20 mA), the focus-skin distance (3–20 cm) and the resulting half 
value layer (4–15 mm) varied.
 Relapse rates according to the patient’s age, tumor localization 
and histological differentiation grade (according to standard cri-
teria  [27] ) were analyzed retrospectively.
 Statistical Analysis 
 GraphPad Prism (version 5.00 for Windows, GraphPad Soft-
ware, San Diego, Calif., USA) was used for statistical analyses. 
Overall and recurrence-free survival, depending on the patient’s 
age, tumor localization and differentiation grade, was analyzed 
using Kaplan-Meier and Cox regression. A p value  ! 0.05 was con-
sidered to be significant; a 95% confidence interval (CI) was com-
puted.
 Results 
 179 patients (66 female [37%], 113 male [63%]) with a 
mean age of 69 years (SD 12.93, 95% CI 61.37–66.53) were 
included, accounting for 180 cSCC lesions which were 
treated with superficial RTx during the mentioned time 
span. One patient was renal transplanted and received 
immunosuppressive medications, 4 patients suffered 
from diabetes mellitus, and 11 patients revealed a malig-
nancy in their history ( tables 1–3 ). Of the 180 lesions, 166 
were primary lesions, and 4 were recurrent and complete-
ly excised before start of RTx. Most of the lesions (86.7%) 
were located on the head and neck. Lesions other than 
from the head and neck area (13.3%) were mostly locat-
ed on the extremities (8.9%). Histological evaluation re-
vealed 98 tumors (54.8%) as well, 33 (18.3%) as moder-
ately and 15 (8.4%) as poorly differentiated. Mean tumor 
size was 3.5 cm 2 (SD 7.5, 95% CI 2.4–4.6) ( tables 1 ,  2 ).
 The lesions were treated with a mean dose fraction-
ation of 4.6 Gy (SD 1.5, 95% CI 4.3–4.8) and a mean cu-
mulative dose of 48.2 Gy (SD 6.6, 95% CI 47.2–49.2) dur-
ing 11.4 sessions (SD 3.4, 95% CI 10.9–11.9). There was a 
significant correlation of tumor size and cumulative dose 
(p  ! 0.00001, two-tailed paired t test). A mean half value 
layer of 7.2 (SD 3.4, 95% CI 6.7–7.7) and a mean focus-skin 
distance of 15.1 cm (SD 4.6, 95% CI 14.5–15.8) were ap-
plied using a mean electric potential of 37.3 kV (SD 8.0, 
Table 1.  Patient characteristics
Sex Age, years
(mean 8 SD)
Treated cSCC Histological
differentiation
T umor localization
primary relapsed good moderate poor head and
neck 
trunk upper
extremities
lower
extremities
genital
Male 113 (114 lesions) 67.2813.9 111 3 57 26 9 103 (90.4%) 1 (0.9%) 6 (5.3%) 3 (2.6%) 1 (0.9%)
Female 66 71.7812.0 66 0 41 7 7 53 (80.3%) 0 (0.0%) 10 (15.2%) 2 (3.0%) 1 (1.5%)
Total 179 (180 lesions) 69.5 177 3 98 33 16 156 (87%) 1 (0.6%) 16 (8.9%) 5 (2.8%) 2 (1.2%)
One male patient had 2 lesions. Percentages apply to lesions per gender.
Table 2.  Tumor localization of the head and neck
E ye Scalp Lips Nose Ear Front Cheek
Male 2 (1.9%) 11 (10.7%) 28 (27.2%) 14 (13.6%) 21 (20.4%) 17 (16.5%) 10 (9.7%)
Female 8 (15.1%) 3 (5.7%) 12 (22.6%) 11 (20.8%) 3 (5.7%) 9 (17.0%) 7 (13.2%)
Total 10 (6.4%) 14 (9.0%) 40 (25.6%) 25 (16.0%) 24 (15.4%) 26 (16.7%) 17 (10.9%)
Percentages apply to lesions per gender.
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95% CI 36.1–38.4) and a mean electric current of 11.0 mA 
(SD 3.2, 95% CI 10.5–11.5) ( table 4 ).
 Follow-up visits were attended for more than 1 year in 
136 patients (75.6%); 69 patients attended for more than 
5 years (38.3%), and 23 (12.8%) for more than 10 years 
(visits every 6 months). The mean follow-up period was 
4.9 years (SD 4.7; 95% CI 4.2–5.6).
 Relapses and Overall Relapse-Free Survival 
 Of the 180 lesions, 24 relapses (13%) were registered 
with a mean delay of 2.7 years (SD 2.98, 95% CI 1.40–3.92) 
after start of superficial RTx. One of these lesions revealed 
lymph node infiltration 1.7 years after treatment. All re-
lapsed cSCCs were originally primary tumors before 
treated with superficial RTx. Except for 1 case which was 
located on the lower limbs, all relapsed cSCCs originated 
from the head and neck area, all deriving from primary 
tumors. Unfortunately, information about the accurate 
localization of the relapses within the radiated area (cen-
ter versus edge) is not retraceable retrospectively. Apart 
from two cases – one patient with colon cancer, one with 
chronic lymphatic leukemia – there is no evidence for im-
munodeficiency in the patients who experienced a relapse 
( table 3 ). The risk for relapses after RTx increased signifi-
cantly with age (p = 0.012) and correlated significantly 
with tumor size (p  1 0.0001, Cox regression). The overall 
relapse-free survival 1, 2, 5 and 10 years after superficial 
RTx was 95.8, 91.5, 86.2 and 80.4%, respectively ( fig. 1 ).
 Relapse-Free Survival and Histological Differentiation 
Grade 
 Histological differentiation grade is known in 81.7% 
(n = 147). Tumor size and histological differentiation cor-
related significantly (p  ! 0.0011, two-tailed paired t test). 
Of these lesions, well differentiated ones relapsed in 11.2% 
(11/98), moderately differentiated ones in 15.2% (5/33) 
and poorly differentiated ones in 25% (4/16). The number 
of cases is too small to reach a significant level, however 
there is a trend for a better outcome for well differenti-
ated cSCCs (p = 0.1). Relapse-free survival after 1, 2, 5 and 
10 years was 97.4, 94.8, 89.3 and 82.1% in well differenti-
ated tumors, 96.3, 88.9, 80.7 and 80.7% in moderately dif-
ferentiated tumors, and 92.9, 85.7, 77.9 and 39.0% in poor-
ly differentiated tumors ( table 5 ;  fig. 1 ,  2 ).
 Relapse-Free Survival and Tumor Localization 
 The number of tumor sites other than the head and 
neck was too small to perform further differentiation. 
Concerning the head and neck area, the distinguished 
sites were classified as areas around the ears, eyes, nose, 
lips, cheeks, scalp, forehead and neck. cSCCs around/at 
the ears and scalp presented significantly higher relapse 
rates (p = 0.025) compared to other sites: five-year re-
lapse-free survival was 69.2% for tumors on the scalp, 
72.2% for tumors around the ears, while lesions around 
the eyes and cheeks revealed 100 and 90.9% five-year re-
lapse-free survival. Tumors located on the remaining 
body parts other than the head and neck area were most-
ly located on the extremities and showed relapse-free sur-
vival of 94.7% at 5 years ( tables 1 ,  2 ,  6 ). Figure 3 illustrates 
3 clinical examples before treatment and clinical out-
come after treatment. Figure 4 shows the histology of an 
SCC (Bowen carcinoma) before and after treatment.
 Discussion 
 For the treatment of superficial cSCCs, different treat-
ment modalities have been approved  [11, 16, 25] , while 
for invasive cSCCs nowadays standard treatment is sur-
Table 3.  Immunosuppressive disorders and relapses
Diagnosis Cases Relapses
Renal transplant recipient 1 0
Prostate cancer 2 0
Breast cancer 4 0
Colon cancer 1 1
Chronic lymphatic leukemia 2 1
Waldenström’s macroglobulinemia 1 0
Non-Hodgkin lymphoma and colon carcinoma 1 0
Diabetes mellitus 4 0
0 10 20 30
70
80
90
100
Years after treatment
Pe
rc
en
t 
re
la
p
se
-f
re
e
 Fig. 1. Overall relapse-free survival. Number of patients at end-
point: 157. 
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gery. Mohs micrographic surgery improves relapse-free 
survival with relapse rates of 1.2–3.5% after 1.5–4 years 
 [13–14, 28] , but direct comparison of Mohs micrograph-
ic surgery to RTx should be performed with caution due 
to inclusion bias. Evaluating larger cSCCs measuring 
 1 2 cm in diameter which were treated with Mohs micro-
graphic surgery, much higher recurrence rates of 25% 
were recorded  [29] . Besides, radical excision of large 
cSCCs or cSCCs localized at difficult sites may lead to 
functional and cosmetic complications with the risk of 
mutilations and dysfunctions. Also for patients of ad-
vanced age who present multiple co-morbidities, wide 
excision – even if tumescent anesthesia is used – may be 
detrimental, and often hospitalization is required in this 
patient group  [13] . 
 Other skin tumors are effectively treated with super-
ficial RTx – basal cell carcinoma with a recurrence rate of 
16% after 5 years, and lentigo maligna and lentigo ma-
ligna melanoma with 7% after 8 years as studies showed 
in the past  [30, 31] . For specific cases, RTx can be supe-
rior to surgery concerning cosmesis and functional re-
sults  [22, 32] even in view of possible late adverse events 
 [33, 34] . Taking these advantages into account, we retro-
spectively evaluated our data on RTx-treated cSCCs over 
a long time period. Further studies registered relapse 
Table 4.  Applied cumulative dose and corresponding lesion size, applied dose fractionation, focus-skin distance, number of treatments, 
half value layer and electric potential
Cumulative
dose, Gy
Cases,
n
Lesion size,
cm
Dose fractionation,
Gy
Focus-skin
distance, cm
Number of 
treatments
Half value 
layer
Electric 
potential, kV
20 2 11.4815.4 480 11.5845 21.2812.0 985.7 9.587.8
24 1 2.580.0 480 20820 080 680 2.680
28 1 0.280.0 480 20830 080 780 480
32 2 0.480.1 880 9.0825 7.184.2 480 3.381
36 3 0.480.3 480 17.3830 084.6 8.780.6 1480
40 14 6.3818.4 5.182.7 13.4835 12.986.6 9.184.2 6.484.2
42 2 0.680.0 581.4 8.5850 14.185.0 8.582.1 11.684.9
44 15 2.986.0 480 14.4832.7 4.684.2 1180 5.181.9
46 1 0.880.0 680 12830 080 880 480
48 84 4.286.7 4.681.5 15.8837 6.284.4 11.282.6 782.7
50 1 0.380.0 480 12830 080 1280 480
52 15 1.581.5 480 15.2835 6.484.1 1380 6.382.8
54 6 4.488.4 4.381.5 14.7840 6.384.1 1487 8.583.3
56 27 2.282.8 4.981.7 15.1842.6 7.183.9 12.483 9.883.6
58 1 3.080.0 280 20840 080 2980 8.180
60 3 4.286.3 480 14.784.3 5.884.6 1580 9.883
61 1 0.480.0 380 20850 080 2280 14.380
64 1 480 12840 080 1080 8.180
Figures are mean 8 SD unless indicated otherwise.
Table 5.  Relapse-free survival after 1, 2, 5 and 10 years in correla-
tion to histological differentiation grade
Histological
differentiation
1 year 2 years 5 years 10 years
Good 97.4% 94.8% 89.3% 82.1%
Moderate 96.3% 88.9% 80.7% 80.7%
Poor 92.9% 85.7% 77.9% 39.0%
Table 6.  Tumor site and relapse-free survival after 1, 2 and 5 years
L ocalization Cases 1 year 2 years 5  years
Eye 10 (5.6%) 100% 100% 100%
Scalp 14 (7.8%) 92.3% 84.6% 69.2%
Lips 40 (22.2%) 87.4% 87.4% 83.6%
Nose 25 (13.9%) 100% 100% 95.2%
Ear 24 (13.3%) 88.9% 77.8% 72.2%
Forehead 26 (14.4%) 100% 94.4% 87.7%
Cheek 17 (9.4%) 100% 100% 90.9%
Others than HN 24 (13.3%) 100% 94.7% 94.7%
HN = Head and neck.
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rates of 7% 6 years after superficial RTx  [35] and control 
rates of up to 80% in another clinical trial including 142 
cSCCs (data are mixed with results of electron beam ther-
apy)  [22] . Another study including 111 patients with SCC 
registered a 5-year cure rate of 92.7%  [36] .
 We found relapse-free survival in 95.8, 91.5 and 86.2% 
of patients 1, 2 and 5 years after RTx in large cSCCs with 
a mean diameter of 3.5 cm 2 . These data are in concor-
dance with most previous studies, although we evaluated 
lesions at high risk of recurrences regarding the averaged 
lesion size of  1 2 cm, which itself has a higher recurrence 
rate  [37] . A mean tumor size of 3.5 cm 2 alone does not 
necessarily imply a situation which is not feasible for sur-
gery, but tumor localization played an additional and im-
portant role in the decision to perform superficial RTx, 
as did the patient’s co-morbidities and the patient’s 
choice.
 We further show that differentiation into histological 
differentiation grades is of great importance regarding 
the excellent outcomes of relapse-free survival of 94.8% 
in well differentiated but only 85.7% in poorly differenti-
ated tumors at 2 years. These data confirm that RTx is not 
recommended for poorly differentiated cSCCs, although 
other treatment options show high recurrence rates in 
these cases as well  [38] . However, it has to be stated that 
these data only provide a trend and are not reliable in this 
case as already mentioned above.
 We found a correlation between clinical outcome and 
tumor localization of the head and neck region showing 
the best prognosis for cSCCs of the eyes (no recurrence 
in 10 patients at 5 years), nose (95.2% recurrence-free) 
and cheeks (90.9% recurrence-free) while lesions from 
the scalp and ears were recurrence-free only in 69.2 and 
72.2%, respectively (data refer to 5-years relapse-free sur-
vival). The underlying reason for the disparities in out-
come may be suggested in the anatomical structures 
with a possible local invasion of the bones or cartilagi-
nous tissue in the latter sites. Unfortunately, data about 
possible invasion cannot be collected retrospectively, but 
we did not register any metastases besides one case of 
cSCC from the scalp who developed lymph node metas-
tases.
 For young patients who present good surgical appli-
cability, total excision should remain the treatment of 
choice. The same applies to immunocompromised pa-
tients though the low number of patients does not allow 
any statistically correct conclusion in this group. Patients 
with xeroderma pigmentosum may also profit from ad-
juvant RTx as case reports show normal response to RTx. 
Their defects in the DNA repair mechanism are believed 
a b
c d
e f
 Fig. 3. cSCC of the lip before ( a ) and after treatment ( b ), of the left 
temple before ( c ) and after treatment ( d ), and of the eyelid before 
( e ) and after treatment ( f ). 
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 Fig. 2. Relapse-free survival depending on grade of differentia-
tion. Number of patients at endpoint: 87 for well, 28 for moder-
ately and 11 for poorly differentiated tumors. Number of patients 
at beginning: 97 for well, 33 for moderately and 15 for poorly dif-
ferentiated tumors. 
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to be specifically induced by UV radiation but not by RTx 
 [39] .
 A limitation of the study is the fact that information 
about the localization of the relapses – e.g. in-field versus 
at the irradiation margins – is lacking. As tumor thick-
ness is not retraceable in the majority of cases, classifica-
tion of the tumors according to the American Joint Com-
mittee on Cancer is not possible. Furthermore, patient 
selection was individually performed and there were no 
standardized inclusion criteria as this was a retrospective 
study. Therefore, biases in patient selection, patient refer-
ral (as this study was performed in a center) and classifi-
cation are possible. Larger prospective clinical trials are 
required to confirm the achieved results.
 Conclusion 
 Superficial RTx is a safe and efficient treatment option 
for cSCCs localized around the mouth, eyes and nose in 
patients for whom surgery is hardly feasible without risk-
ing considerable side effects. It is particularly favorable 
for elderly patients for whom surgery would be an in-
creased health risk and if functional or cosmetic impair-
ment is expected.
 Disclosure Statement 
 The authors have no conflict of interest or financial support to 
disclose. 
a b
c d
 Fig. 4. Histology of a cSCC (Bowen carcinoma) before ( a ,  b ) and after treatment ( c ,  d ). H&E staining. 
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